Aeruguard

 
 

Aeruguard is a single-strain inhaled biotherapeutic that treats Pseudomonas aeruginosa and breaks down mucus in Cystic Fibrosis patients. Consisting of a live Lactobacillus hybrid, it is designed specifically to kill Pseudomonas and reduce the viscosity and volume of mucus. Aeruguard also down-regulates the inflammatory immune response created by the Pseudomonas pathogen and reduces scarring in the lungs. 


SciBac is expanding its pipeline by developing biotherapeutics for other antibiotic resistant diseases.